Miniatura

Fitxers

723809.pdf (74.07 KB)

Tipus de document

Article

Versió

Versió enviada

Data de publicació

2022-05

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/187104

A New Family of Subnanomolar inhibitors of Soluble Epoxide Hydrolase The FASEB journal, 13 May 2022, 36, supplement 1

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1096/fasebj.2022.36.S1.R2281

Resum

The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of epoxyeicosatrienoic acids, endogenous chemical mediators derived from arachidonic acid that show anti-inflammatory and analgesic effects.1 Although several potent sEH inhibitors (sEHI) have been developed, including clinical candidates AR9281, GSK2256294, and EC5026, so far no sEHI has reached the market.2 Recently, a new series of benzohomoadamantane-based ureas endowed with potent inhibitory activity for the human and murine sEH was reported. However, their very low microsomal stability prevented further development.3 Herein, novel series of benzohomoadamantane-based ureas were synthesized, fully characterized, and evaluated as sEHI. Most of them were endowed with subnanomolar inhibitory potencies at the human and murine enzymes. Further in vitro profiling (solubility, cytotoxicity, metabolic stability, CYP450s, hLOX-5, hCOX-2, hERG inhibition, permeability) allowed us to select a candidate for efficacy studies. In summary, these novel results and the previously reported studies using other families of sEHI, strongly suggest that sEH may be a target of clinical interest for the treatment of inflammatory and pain-related disorders.4 References: 1-Morisseau, C.; Hammock, B. D. Annu.Rev. Pharmacol. Toxicol. 2013, 53, 37-58. 2-Sun, C.-P.; Zhang, X.-Y.; Morisseau, C.; Hwang, S. H.; Zhang, Z.-J.; Hammock, B. D.; Ma, X.-C. J. Med. Chem. 2021, 64, 184-215. 3-Codony, S.; Calvó-Tusell, C.; Valverde, E.; Osuna, S.; Morisseau, C.; Loza, M. I.; Brea, J.; Pérez, C.; Rodríguez-Franco, M. I.; Pizarro-Delgado, J.; Corpas, R.; Griñán-Ferré, C.; Pallàs, M.; Sanfeliu, C.; Vázquez-Carrera, M.; Hammock, B. D.; Feixas, F.; Vázquez, S. J. Med. Chem., 2021, 64, 5429-5446. 4-McReynolds, C.; Morisseau, C.; Wagner, K.; Hammock, B. D. Adv. Exp. Med. Biol. 2020, 1274, 71-99.

Matèries

Desenvolupament de medicaments, Inflamació, Química farmacèutica

Matèries (anglès)

Drug development, Inflammation, Pharmaceutical chemistry

Citació

Col·leccions

Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Citació

ESCOLANO MIRÓN, Carmen, BAGAN POLONIO, Andrea, TURCU, Andreea l., MORISSEAU, Christophe, LOZA, María isabel, BREA, José, BARTRA, Clara, SANFELIU I PUJOL, Coral, HAMMOCK, Bruce d., VÁZQUEZ CRUZ, Santiago. A New Family of Subnanomolar inhibitors of Soluble Epoxide Hydrolase The FASEB journal, 13 May 2022, 36, supplement 1. _The FASEB Journal _. 2022. Vol. 36, núm. S1. [consulta: 25 de febrer de 2026]. ISSN: 0892-6638. [Disponible a: https://hdl.handle.net/2445/187104]

Exportar metadades

JSON - METS

Compartir registre